Abstract:Newborn screening (NBS) plays a significant role in reducing the risk of birth defects. NBS in China began in the early 1980s. Under the protection of laws and regulations and the leadership of the national health administration, approved screening centers in public hospitals took the responsibility for publicity, screening, diagnosis, treatment, follow-up and management of birth defects. As of 2022, 31 provinces (autonomous regions and municipalities directly under the central government) have carried out NBS for phenylketonuria, congenital hypothyroidism, and hearing loss, 23 provinces have carried out screening for glucose-6-phosphate dehydrogenase (with a screening rate of 89.24%), and 24 provinces have carried out screening for congenital adrenal cortical hyperplasia (91.45% screening rate). Over the past four decades, screening techniques have evolved from bacterial inhibition, fluorescence analysis, and tandem mass spectrometry for the detection of biochemical markers to genetic testing, which has greatly contributed to the expansion of the types of diseases screened for. The combined use of metabolomics and genomics is currently being explored. Effective management and rigorous quality control of NBS are prerequisites for improving the quality and ensuring the accuracy of screening. The Quality Management System for Newborn Screening System Network (QMS-NBS), established by the National Center for Clinical Laboratories, covers all screening centers and related blood collection agencies. The operation of the QMS-NBS allows the quality and performance of screening to be transparent and measurable, ensuring the quality and efficiency of screening. This article provides an overview of the history of NBS, especially the evolution of policies for the NBS in China, the construction of screening institutions, the number of newborns screened, the incidence rates of screened diseases, the changes in screening technology, the expansion of new diseases screened for, and the quality control of NBS. Overall, the progress in NBS in China has not only benefited from the development and standardization at the technological level, but also benefited from the construction of policies, regulations and ethics.

Mandatory newborn screening in the United States: History, current status, and existential challenges

Newborn Screening: Education, Consent, and the Residual Blood Spot. The Position of the National Society of Genetic Counselors

Promises and challenges of genomic newborn screening (NBS) – lessons from public health NBS programs

Critical role of the March of Dimes in the expansion of newborn screening

Problems and reflection on the screening and diagnosis for disease of newborn

A Multicenter Prospective Study of Next-Generation Sequencing-Based Newborn Screening for Monogenic Genetic Diseases in China

Newborn screening for genetic disorders: Current status and prospects for the future

Study of the Administrative Approach of Newborns Screening in Zhejiang Province

Progress of newborn screening in China

Newborn bloodspot screening policy framework for Australia

Assessing interstate racial and socioeconomic disparities in newborn screening policies in the United States

Defining the Minimal Long-Term Follow-Up Data Elements for Newborn Screening

Newborn Screening in Developing Countries: The Need of the Hour

Newborn Screening in the Era of Precision Medicine.

A Children's Rights Framework for Genomic Medicine: Newborn Screening as a Use Case

Genomic sequencing for newborn screening: current perspectives and challenges

Improving newborn screening in India: Disease gaps and quality control

Progress in treatment and newborn screening for Duchenne muscular dystrophy and spinal muscular atrophy

Pain points in parents’ interactions with newborn screening systems: a qualitative study

Australian Public Perspectives on Genomic Newborn Screening: Risks, Benefits, and Preferences for Implementation

NBSTRN Tools to Advance Newborn Screening Research and Support Newborn Screening Stakeholders